


How similar is this cluster to the other clusters?

Genes in the cluster along with the pathways as annotated by experts


Expert Annotation		
Treatment	Pathway	Regulation Type
RHOA_Q63L	Canonical Cytoskeletal Re-org	Activator
PRKACA_WT.1	Canonical PKA	Activator
PRKACA_WT.2	Canonical PKA	Activator
GLI1_WT	Hedgehog	Activator




Top 5 genes negatively correlated to the cluster

Expert Annotation			Mean Correlation	Standard Deviation
Treatment	Pathway	Regulation Type		
CSNK1A1.WT.3	Canonical WNT	Inhibitor	-0.54	0.07
RPS6KB1.WT.1	Canonical TOR	Activator	-0.54	0.10
AKT1.WT.1	Canonical PI3K/AKT	Activator	-0.50	0.08
STK11.WT.2	Canonical TOR	Inhibitor	-0.49	0.09
MAPKAP1.WT	Canonical TOR	Activator	-0.49	0.15


What groups of morphological features are distinguishing in the cluster relative to the untreated samples? (maximum of absolute m-score for the features belonging to the same category; m-score defined as median of a feature z-score across genes in the cluster) Black means no feature is available in the category



Which individual morphological features are distinguishing in the cluster relative to the untreated samples? Blue/Red means the feature has a positive/negative z-score. Size is proportional to the z-score value.



How strongly are genes within the cluster correlated?



Empty

Plate : 41744 - Genes in the Cluster (Channels are sorted based on their dominance in the grid plot)






GLI1.WT

PRKACA.WT.1





PRKACA.WT.2









RHOA.Q63L

RNA




DNA



Compound IDs and common names (where available); blue/red colored box means the matching compound is positively/negatively correlated with the cluster	Chemical structure	Mean pairwise replicates correlation of the compound signature (95th DMSO replicate correlation is 0.52)	Mean \pm standard deviation correlation between compound and each gene in cluster; Tables contain data for individual genes	Mean compound rank when scored against genes in cluster using L1000 profiling \pm standard deviation; Tables contain data for individual genes	How similar is the compound signature to the gene clusters in this experiment? (Yellow and red lines correspond to top/bottom 1st and 5th percentile DMSO correlation to all the genes)	Common distinguishing feature categories in the compound and genes in the cluster relative to the untreated samples	Distinguishing individual features for the compound relative to untreated samples. Black means a mismatch; i.e. active (= high z-score in magnitude) in the compound, and either inactive (= small z-score in magnitude) or oppositely active in the gene cluster	Number of PubChem assays in which the compound was tested; assays in which the compound was active are itemized																				
BRD-K92570288-001-01-7 PubChem CID : 54614939		0.91 (in 4 replicates)	<table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI1_WT</td><td>0.70</td></tr><tr><td>PRKACA_WT.1</td><td>0.76</td></tr><tr><td>PRKACA_WT.2</td><td>0.77</td></tr><tr><td>RHOA_Q63L</td><td>0.76</td></tr></table>	Treatment	Score	GLI1_WT	0.70	PRKACA_WT.1	0.76	PRKACA_WT.2	0.77	RHOA_Q63L	0.76	<table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI1_WT</td><td>0.936</td></tr><tr><td>PRKACA_WT.1</td><td>0.937</td></tr><tr><td>PRKACA_WT.2</td><td>0.950</td></tr><tr><td>RHOA_Q63L</td><td>0.939</td></tr></table>	Treatment	Score	GLI1_WT	0.936	PRKACA_WT.1	0.937	PRKACA_WT.2	0.950	RHOA_Q63L	0.939				Total number of assays tested in: 19
Treatment	Score																											
GLI1_WT	0.70																											
PRKACA_WT.1	0.76																											
PRKACA_WT.2	0.77																											
RHOA_Q63L	0.76																											
Treatment	Score																											
GLI1_WT	0.936																											
PRKACA_WT.1	0.937																											
PRKACA_WT.2	0.950																											
RHOA_Q63L	0.939																											
BRD-K86981519-001-01-5 PubChem CID : 44496872		0.91 (in 4 replicates)	<table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI1_WT</td><td>0.64</td></tr><tr><td>PRKACA_WT.1</td><td>0.65</td></tr><tr><td>PRKACA_WT.2</td><td>0.65</td></tr><tr><td>RHOA_Q63L</td><td>0.67</td></tr></table>	Treatment	Score	GLI1_WT	0.64	PRKACA_WT.1	0.65	PRKACA_WT.2	0.65	RHOA_Q63L	0.67	<table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI1_WT</td><td>0.632</td></tr><tr><td>PRKACA_WT.1</td><td>0.671</td></tr><tr><td>PRKACA_WT.2</td><td>0.703</td></tr><tr><td>RHOA_Q63L</td><td>0.687</td></tr></table>	Treatment	Score	GLI1_WT	0.632	PRKACA_WT.1	0.671	PRKACA_WT.2	0.703	RHOA_Q63L	0.687				Total number of assays tested in: 29
Treatment	Score																											
GLI1_WT	0.64																											
PRKACA_WT.1	0.65																											
PRKACA_WT.2	0.65																											
RHOA_Q63L	0.67																											
Treatment	Score																											
GLI1_WT	0.632																											
PRKACA_WT.1	0.671																											
PRKACA_WT.2	0.703																											
RHOA_Q63L	0.687																											




BRD-A61437901-001-06-4
AC1MELUG
MLS001034555
HMS2964O04
STK056804
SMR000664698
ST50589848
PubChem CID : 2905407



0.92 (in 2 replicates)

Treatment	Score
GLI1.WT	0.09
PRKACA.WT.1	0.02
PRKACA.WT.2	0.02
RHOA.Q63L	0.75


NA



Total number of assays tested in: 505. Active in the following assays:

- Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7). (AID 1861)
- Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T. Cruzi Replication (AID 1885)
- Fluorescence-based confirmation cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7). (AID 1952)
- Luminescence Cell-Based/Microorganism Dose Confirmation HTS to Identify Inhibitors of T. Cruzi Replication (AID 204)
- Fluorescence-based counterscreen for antagonists of the G-protein coupled receptor 7 (GPR7): cell-based high throughput screening assay to identify antagonists of the melanin-concentrating hormone receptor 1 (MCHRL1). (AID 2148)
- Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the Oxytocin Receptor (OXTR). (AID 2435)
- Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R). (AID 2597)
- Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the m1 1 (OPRM1) and delta 1 (OPRD1) opioid receptors (AID 504326)
- Antagonist of Human D1 Dopamine Receptor: qHTS (AID 504652)
- Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS (AID 504660)
- Primary qHTS for delayed dose inhibitors of the malarial parasite plasmod, 48 hour incubation (AID 504832)
- Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1) (AID 588814)
- Full cell counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line (AID 602248)
- Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5) (AID 624037)
- Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 6 (CHRM6) (AID 624127)
- Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1) (AID 624466)
- Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1) (AID 624467)
- qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT (AID 686979)
- qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS (AID 720551)
- qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS (AID 720553)
- qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS (AID 720579)




BRD-K28901743-001-05-3
ZINC01748812
AC1LTAWC
MLS000552933
ZINC1748812
CCG-15676
STL331422
BAS 00558059
SMR000175471
ST50181975
PubChem CID : 1555494



NA (in 1 replicates)

Treatment	Score
GLI1.WT	0.06
PRKACA.WT.1	0.64
PRKACA.WT.2	0.63
RHOA_Q63L	0.72


NA



Total number of assays tested in: 626. Active in the following assays:

- Screen for Chemicals that Extend Yeast Lifespan (AID 777)
- hHTS identification of small molecule inhibitors of tim01Δ yeast via a luminescent assay (AID 463190)
- Single concentration confirmation of small molecule inhibitors of tim01Δ yeast via a luminescent assay (AID 462313)
- Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of *M. tuberculosis* (AID 588726)
- Fluorescence Intensity-based biochemical primary high throughput screening assay to identify inhibitors of kallikrein-7 (K7) zymogen (AID 625089)
- Fluorescence Intensity-based biochemical primary high throughput confirmation assay to identify activators of kallikrein-7 (K7) zymogen (AID 686049)
- Counter screen for activators of kallikrein-7 (K7) zymogen: Fluorescence intensity-based biochemical high throughput counter screen assay for activators that optically interfere with the measurement of EDANS-DABCYL fluorescence (AID 686952)




BRD-K52251545-001-05-2
AC1M5VPS
MLS000418615
HMS2531C16
ZINC3270008
SMR000247565
T0510-7581
PubChem CID : 2386323



0.80 (in 4 replicates)













Treatment	Score
GLI1.WT	0.60
PRKACA.WT.1	0.67
PRKACA.WT.2	0.69
RHOA.Q63L	0.66

NA



Total number of assays tested in: 629. Active in the following assays:

- Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 (AID 1479)
- Antagonist of Human D 1 Dopamine Receptor: qHTS (AID 504652)
- High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set (AID 588497)

<div>BRD-K20428666-003-06-2</div> <div>MLS000672046</div> <div>SMR000293477</div> <div>AC1MHCD3</div> <div>PubChem CID : 2949708</div>	<div></div>	NA (in 1 replicates)	<div>0.65 ± 0.04</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI-WT</td><td>0.69</td></tr><tr><td>PRKACA-WT1</td><td>0.65</td></tr><tr><td>PRKACA-WT2</td><td>0.61</td></tr><tr><td>RHOA-Q68L</td><td>0.66</td></tr></table>	Treatment	Score	GLI-WT	0.69	PRKACA-WT1	0.65	PRKACA-WT2	0.61	RHOA-Q68L	0.66	NA	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 616. Active in the following assays:</div> <ul style="list-style-type: none">• qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1) (AID 1030)• Leishmania major promastigote HTS (AID 1063)• qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase) (AID 1490)• Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype (AID 1531)• Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7). (AID 1861)• Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication (AID 1885)• High Throughput Screen of 100,000 compound library to Identify Inhibitors of Mycobacterium tuberculosis H37Rv (AID 1949)• Fluorescence-based confirmation cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7). (AID 1952)• Fluorescence-based counterscreen for antagonists of the G-protein coupled receptor 7 (GPR7): cell-based high throughput screening assay to identify antagonists of the melanin-concentrating hormone receptor 1 (MCHRL1). (AID 2148)• VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity (AID 2546)• HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists (AID 485344)• Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R (AID 540308)• HTS Assay for Peg3 Promoter Inhibitors (AID 588405)• nHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay (AID 602449)• Dose response confirmation of nHTS inhibitor hits of the mitochondrial permeability transition pore via an absorbance assay (AID 651564)• Dose response confirmation of nHTS inhibitor hits of the mitochondrial permeability transition pore via a fluorescence based counterscreen assay (AID 651564)• Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPNC Compound Library (AID 651702)• qHTS Assay for Inhibitors of Hepatitis C Virus (HCV) (AID 651820)• Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with compounds from Cherry Pick01 (AID 651954)• qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line (AID 686970)• qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line (AID 686971)• qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT (AID 686978)• qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT (AID 686979)• qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen (AID 743279)										
Treatment	Score																											
GLI-WT	0.69																											
PRKACA-WT1	0.65																											
PRKACA-WT2	0.61																											
RHOA-Q68L	0.66																											
<div>BRD-K27496085-001-06-9</div> <div>MLS000762893</div> <div>SMR000439717</div> <div>AC1LXW72</div> <div>BDBM58089</div> <div>HMS2785113</div> <div>HMS3469C13</div> <div>ZINC8657900</div> <div>STK848802</div> <div>ZINC08657900</div> <div>ST50782147</div> <div>T6363733</div> <div>F3348-0380</div> <div>PubChem CID : 1838594</div>	<div></div>	NA (in 1 replicates)	<div>0.65 ± 0.03</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI-WT</td><td>0.67</td></tr><tr><td>PRKACA-WT1</td><td>0.64</td></tr><tr><td>PRKACA-WT2</td><td>0.61</td></tr><tr><td>RHOA-Q68L</td><td>0.68</td></tr></table>	Treatment	Score	GLI-WT	0.67	PRKACA-WT1	0.64	PRKACA-WT2	0.61	RHOA-Q68L	0.68	NA	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 569. Active in the following assays:</div> <ul style="list-style-type: none">• HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells. (AID 1377)• High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv (AID 1626)• MLPNC Streptokinase Expression Inhibition (AID 1662)• Luminescence Microorganism-Based Dose Confirmation HTS to Identify Compounds Cytotoxic to SK(-)GAS Group A Streptococcus (AID 1900)• Luminescence Microorganism-Based Dose Confirmation HTS to Identify Inhibitors of Streptokinase Promotor Activity (AID 1902)• Luminescence Microorganism-Based Dose Response HTS to Identify Compounds Cytotoxic to Streptococcus (AID 1915)• qHTS for inhibitors of ROR gamma transcriptional activity (AID 2551)• Primary qHTS for delayed death inhibitors of the malarial parasite plasid, 48 hour incubation (AID 504832)• nHTS identification of small molecule Triacylglycerol inhibitors in a fluorescence assay (AID 651582)• Single concentration confirmation of small molecule Triacylglycerol inhibitors in a fluorescence assay (AID 651629)• qHTS of TDP-43 Inhibitors (AID 652104)• qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT (AID 686978)										
Treatment	Score																											
GLI-WT	0.67																											
PRKACA-WT1	0.64																											
PRKACA-WT2	0.61																											
RHOA-Q68L	0.68																											
<div>BRD-K91098396-001-01-9</div> <div>PubChem CID : 54619176</div>	<div></div>	0.85 (in 4 replicates)	<div>0.65 ± 0.05</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI-WT</td><td>0.72</td></tr><tr><td>PRKACA-WT1</td><td>0.65</td></tr><tr><td>PRKACA-WT2</td><td>0.61</td></tr><tr><td>RHOA-Q68L</td><td>0.62</td></tr></table>	Treatment	Score	GLI-WT	0.72	PRKACA-WT1	0.65	PRKACA-WT2	0.61	RHOA-Q68L	0.62	<div>0.213 ± 0.343</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI-WT</td><td>0.757</td></tr><tr><td>PRKACA-WT1</td><td>0.642</td></tr><tr><td>PRKACA-WT2</td><td>0.685</td></tr><tr><td>RHOA-Q68L</td><td>0.647</td></tr></table>	Treatment	Score	GLI-WT	0.757	PRKACA-WT1	0.642	PRKACA-WT2	0.685	RHOA-Q68L	0.647	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 37.</div>
Treatment	Score																											
GLI-WT	0.72																											
PRKACA-WT1	0.65																											
PRKACA-WT2	0.61																											
RHOA-Q68L	0.62																											
Treatment	Score																											
GLI-WT	0.757																											
PRKACA-WT1	0.642																											
PRKACA-WT2	0.685																											
RHOA-Q68L	0.647																											

BRD-K70783599-001-06-5

ST50133582

AC1LQBW4

MLS000662655

HMS2706O12

ZINC1151909

STK987650

SMR000270095

PubChem CID : 1322062

Cc1cc2c(c1)cc3c2c(c4c3nc5c4cnc5)cc6c4cnc6

NA (in 1 replicates)

0.64 ± 0.04

Treatment

Score

GLI-WT

0.68

PRKACA-WT.1

0.62

PRKACA-WT.2

0.59

BRCA-QSBL

0.67

NA

BRD-A08917095-001-05-9

SMR000118767

MLS000121336

AC1MKVL1

MLS002534485

HMS2327D07

ASN 05560082

PubChem CID : 3210440

CC(C)C1=CN=C(C2=CC=CC=C2C(=O)N1C3=CC=CC=C3)C4=CC=CC=C4

NA (in 1 replicates)

0.61 ± 0.05

Treatment

Score

GLI-WT

0.63

PRKACA-WT.1

0.60

PRKACA-WT.2

0.54

BRCA-QSBL

0.66

NA

BRD-A90037676-001-05-2

AC1MNLZO

MLS000678997

HMS2738D22

SMR000323385

F0762-0511

PubChem CID : 3354871

CCCCCNC(=O)Cc1ccc2ccccc2c1

NA (in 1 replicates)

-0.73 ± 0.02

Treatment

Score

GLI-WT

-0.73

PRKACA-WT.1

-0.71

PRKACA-WT.2

-0.74

BRCA-QSBL

-0.75

NA

BRD-K00659699-001-05-3

MLS000392966

SMR000248123

T5227208

AC1MSJKL

MLS002634504

BDBM68072

HMS2547C15

ZINC9631316

ZINC9631316

PubChem CID : 3560290

Cc1cc2c(c1)cc3c2c(c4c3nc5c4cnc5)cc6c4cnc6

NA (in 1 replicates)

-0.67 ± 0.04

Treatment

Score

GLI-WT

-0.71

PRKACA-WT.1

-0.66

PRKACA-WT.2

-0.68

BRCA-QSBL

-0.70

NA

BRD-K42950654-001-01-9

PubChem CID : 54646040

Cc1cc2c(c1)cc3c2c(c4c3nc5c4cnc5)cc6c4cnc6

NA (in 1 replicates)

-0.67 ± 0.06

Treatment

Score

GLI-WT

-0.64

PRKACA-WT.1

-0.60

PRKACA-WT.2

-0.70

BRCA-QSBL

-0.71

0.198 ± 0.155

Treatment

Score

GLI-WT

0.223

PRKACA-WT.1

0.278

PRKACA-WT.2

0.084

BRCA-QSBL

0.064














- Total number of assays tested in: 631. Active in the following assays:
- HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near-saturating concentration of mannose 6-phosphat (AID 1216)
 - Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation (AID 1285)
 - MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors (AID 1813)
 - HCS assay for microtubule stabilizers (AID 2205)
 - uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation (AID 435003)
 - Fluorescent Polarization Homogeneous Dose Retest to Confirm Inhibitors of Mxv-5 Binding to TCR-2 (AID 449745)
 - High-content cell-based screening for modulators of autophagy (AID 463193)
 - qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a (AID 504332)
 - Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity (AID 504648)
 - Cholera Quorum: HTS for inducers of light production in the absence of autoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader 2132-01 Agonist-SinglePoint- HTS-Activity (AID 588436)
 - A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (AID 624296)
 - A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (AID 624297)
 - uHTS identification of small molecule Triacylglycerol inhibitors in a fluorescence assay (AID 651582)
 - Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Flt1 transcriptional activity Measured in Cell-Based System Using Plate Reader - 7034-01 Inhibitor-SinglePoint- HTS-Activity (AID 651661)
 - MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01 Inhibitor-SinglePoint- HTS-Activity (AID 651687)
 - qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line (AID 686970)
 - qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line (AID 686971)
 - qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT (AID 686978)
 - qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT (AID 686979)

- Total number of assays tested in: 678. Active in the following assays:
- HCS for Compounds that Down-Regulate Insulin Promoter Activity in MING Cells (AID 1628)
 - Phenotypic HTS multiplex for antifungal efflux pump inhibitors (AID 485275)
 - Primary qHTS for delayed death inhibitors of the malarial parasite plasmod, 48 hour incubation (AID 504832)

- Total number of assays tested in: 622. Active in the following assays:
- Aqueous Solubility from MLSMR Stock Solutions (AID 1996)
 - qHTS for inhibitors of ROR gamma transcriptional activity (AID 2551)

- Total number of assays tested in: 618. Active in the following assays:
- Screen for Chemicals that Inhibit the RAM Network (AID 868)
 - Leishmania major promastigote HTS (AID 1063)
 - Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Confirmatory Screen (AID 1361)
 - Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen (AID 1362)
 - MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators (AID 1814)
 - High Content Assay for Compounds that inhibit the Assembly of the Perinuclear Compartment (AID 2417)
 - qHTS for inhibitors of ROR gamma transcriptional activity (AID 2551)
 - HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress (AID 2732)
 - Assay for HTS of G1/Go-linked GPCRs using mGluR5: Primary Screening (AID 488969)
 - CHOP Confirmatory Screen (AID 504437)
 - Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A) (AID 588511)
 - uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay (AID 602449)
 - Activators of the GIRK family of Potassium Channels (GIRK-Confirmatory-CRC) (AID 623909)
 - Activators of the GIRK family of Potassium Channels (GIRK1/2-Confirmatory) (AID 623911)
 - Single concentration confirmation of uHTS inhibitor hits of the mitochondrial permeability transition pore via a fluorescent based assay (AID 624504)
 - qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line (AID 686971)
 - qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT (AID 686979)

Total number of assays tested in: 42.

BRD-K58469266-001-01-0 PubChem CID : 54646063		NA (in 1 replicates)	<div><div>-0.67 ± 0.04</div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI-WT</td><td>-0.64</td></tr><tr><td>PRKACA-WT1</td><td>-0.64</td></tr><tr><td>PRKACA-WT2</td><td>-0.68</td></tr><tr><td>BRDQA-QSBL</td><td>-0.71</td></tr></table></div> <div><div>0.557 ± 0.192</div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI-WT</td><td>0.770</td></tr><tr><td>PRKACA-WT1</td><td>0.339</td></tr><tr><td>PRKACA-WT2</td><td>0.411</td></tr><tr><td>BRDQA-QSBL</td><td>0.606</td></tr></table></div>	Treatment	Score	GLI-WT	-0.64	PRKACA-WT1	-0.64	PRKACA-WT2	-0.68	BRDQA-QSBL	-0.71	Treatment	Score	GLI-WT	0.770	PRKACA-WT1	0.339	PRKACA-WT2	0.411	BRDQA-QSBL	0.606				Total number of assays tested in: 39.
Treatment	Score																										
GLI-WT	-0.64																										
PRKACA-WT1	-0.64																										
PRKACA-WT2	-0.68																										
BRDQA-QSBL	-0.71																										
Treatment	Score																										
GLI-WT	0.770																										
PRKACA-WT1	0.339																										
PRKACA-WT2	0.411																										
BRDQA-QSBL	0.606																										
BRD-K52525325-001-01-4 PubChem CID : 54641100		NA (in 1 replicates)	<div><div>-0.67 ± 0.04</div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI-WT</td><td>-0.60</td></tr><tr><td>PRKACA-WT1</td><td>-0.61</td></tr><tr><td>PRKACA-WT2</td><td>-0.67</td></tr><tr><td>BRDQA-QSBL</td><td>-0.69</td></tr></table></div> <div>NA</div>	Treatment	Score	GLI-WT	-0.60	PRKACA-WT1	-0.61	PRKACA-WT2	-0.67	BRDQA-QSBL	-0.69				Total number of assays tested in: 37.										
Treatment	Score																										
GLI-WT	-0.60																										
PRKACA-WT1	-0.61																										
PRKACA-WT2	-0.67																										
BRDQA-QSBL	-0.69																										
BRD-K16845730-001-05-1 AC1O1J1C MLS000416701 SMR000241729 PubChem CID : 6074706		NA (in 1 replicates)	<div><div>-0.66 ± 0.03</div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI-WT</td><td>-0.70</td></tr><tr><td>PRKACA-WT1</td><td>-0.64</td></tr><tr><td>PRKACA-WT2</td><td>-0.65</td></tr><tr><td>BRDQA-QSBL</td><td>-0.66</td></tr></table></div> <div>NA</div>	Treatment	Score	GLI-WT	-0.70	PRKACA-WT1	-0.64	PRKACA-WT2	-0.65	BRDQA-QSBL	-0.66				Total number of assays tested in: 564. Active in the following assays: <ul style="list-style-type: none">• qHTS Assay for Inhibitors of <i>Bacillus subtilis</i> Stp phosphopantetheinyl transferase (PPTase) (AID 1490)• qHTS Assay for Inhibitors of BAZ2B (AID 504333)• qHTS Assay for Inhibitors of JMJD2A-Tudor Domain (AID 504339)• Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation (AID 504834)• qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project) (AID 588342)• A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (AID 624297)• Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01 Inhibitor.SinglePoint.HTS.Activity (AID 651704)• qHTS Assay for Inhibitors of Hepatitis C Virus (HCV) (AID 651820)• qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDPI): qHTS in cells in absence of CPT (AID 686978)• qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDPI): qHTS in cells in presence of CPT (AID 686979)• Alphascreen Interference Assay Measured in Biochemical System Using Plate Reader - 2160-02 Inhibitor.Dose.CherryPick.Activity (AID 720494)• Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01 Inhibitor.Dose.CherryPick.Activity (AID 720495)• qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen (AID 720504)• Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of stailic acid acetyltransferase (SIAT) (AID 1053197)										
Treatment	Score																										
GLI-WT	-0.70																										
PRKACA-WT1	-0.64																										
PRKACA-WT2	-0.65																										
BRDQA-QSBL	-0.66																										
BRD-K74659043-001-01-6 PubChem CID : 54646039		NA (in 1 replicates)	<div><div>-0.66 ± 0.06</div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI-WT</td><td>-0.62</td></tr><tr><td>PRKACA-WT1</td><td>-0.59</td></tr><tr><td>PRKACA-WT2</td><td>-0.67</td></tr><tr><td>BRDQA-QSBL</td><td>-0.74</td></tr></table></div> <div>0.479 ± 0.256</div>	Treatment	Score	GLI-WT	-0.62	PRKACA-WT1	-0.59	PRKACA-WT2	-0.67	BRDQA-QSBL	-0.74				Total number of assays tested in: 41.										
Treatment	Score																										
GLI-WT	-0.62																										
PRKACA-WT1	-0.59																										
PRKACA-WT2	-0.67																										
BRDQA-QSBL	-0.74																										
BRD-K98170723-003-05-0 MLS001209415 SMR000514306 PubChem CID : 23724450		NA (in 1 replicates)	<div><div>-0.65 ± 0.06</div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI-WT</td><td>-0.72</td></tr><tr><td>PRKACA-WT1</td><td>-0.61</td></tr><tr><td>PRKACA-WT2</td><td>-0.59</td></tr><tr><td>BRDQA-QSBL</td><td>-0.65</td></tr></table></div> <div>NA</div>	Treatment	Score	GLI-WT	-0.72	PRKACA-WT1	-0.61	PRKACA-WT2	-0.59	BRDQA-QSBL	-0.65				Total number of assays tested in: 494. Active in the following assays: <ul style="list-style-type: none">• Aqueous Solubility from MLSMR Stock Solutions (AID 1996)• qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDPI): qHTS in cells in absence of CPT (AID 686978)• qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDPI): qHTS in cells in presence of CPT (AID 686979)• qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen (AID 743279)										
Treatment	Score																										
GLI-WT	-0.72																										
PRKACA-WT1	-0.61																										
PRKACA-WT2	-0.59																										
BRDQA-QSBL	-0.65																										
BRD-K76988892-001-01-9 PubChem CID : 54646031		NA (in 1 replicates)	<div><div>-0.64 ± 0.03</div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI-WT</td><td>-0.62</td></tr><tr><td>GLI-WT</td><td>0.293</td></tr><tr><td>PRKACA-WT1</td><td>-0.63</td></tr><tr><td>PRKACA-WT2</td><td>-0.64</td></tr><tr><td>BRDQA-QSBL</td><td>-0.69</td></tr></table></div> <div>0.292 ± 0.130</div>	Treatment	Score	GLI-WT	-0.62	GLI-WT	0.293	PRKACA-WT1	-0.63	PRKACA-WT2	-0.64	BRDQA-QSBL	-0.69				Total number of assays tested in: 41.								
Treatment	Score																										
GLI-WT	-0.62																										
GLI-WT	0.293																										
PRKACA-WT1	-0.63																										
PRKACA-WT2	-0.64																										
BRDQA-QSBL	-0.69																										
BRD-K86846131-001-01-8 PubChem CID : 54645940		NA (in 1 replicates)	<div><div>-0.64 ± 0.08</div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI-WT</td><td>-0.55</td></tr><tr><td>PRKACA-WT1</td><td>0.043</td></tr><tr><td>PRKACA-WT2</td><td>-0.67</td></tr><tr><td>BRDQA-QSBL</td><td>-0.75</td></tr></table></div> <div>0.170 ± 0.120</div>	Treatment	Score	GLI-WT	-0.55	PRKACA-WT1	0.043	PRKACA-WT2	-0.67	BRDQA-QSBL	-0.75				Total number of assays tested in: 43.										
Treatment	Score																										
GLI-WT	-0.55																										
PRKACA-WT1	0.043																										
PRKACA-WT2	-0.67																										
BRDQA-QSBL	-0.75																										